Cargando…
Management of splanchnic vein thrombosis
The expression splanchnic vein thrombosis encompasses Budd-Chiari syndrome and portal vein thrombosis. These disorders have common characteristics: they are both rare diseases which can cause portal hypertension and its complications. Budd-Chiari syndrome and portal vein thrombosis in the absence of...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023986/ https://www.ncbi.nlm.nih.gov/pubmed/36941824 http://dx.doi.org/10.1016/j.jhepr.2022.100667 |
_version_ | 1784909008274980864 |
---|---|
author | Elkrief, Laure Payancé, Audrey Plessier, Aurélie d’Alteroche, Louis Ronot, Maxime Paradis, Valérie Valla, Dominique Rautou, Pierre-Emmanuel |
author_facet | Elkrief, Laure Payancé, Audrey Plessier, Aurélie d’Alteroche, Louis Ronot, Maxime Paradis, Valérie Valla, Dominique Rautou, Pierre-Emmanuel |
author_sort | Elkrief, Laure |
collection | PubMed |
description | The expression splanchnic vein thrombosis encompasses Budd-Chiari syndrome and portal vein thrombosis. These disorders have common characteristics: they are both rare diseases which can cause portal hypertension and its complications. Budd-Chiari syndrome and portal vein thrombosis in the absence of underlying liver disease share many risk factors, among which myeloproliferative neoplasms represent the most common; a rapid comprehensive work-up for risk factors of thrombosis is needed in these patients. Long-term anticoagulation is indicated in most patients. Portal vein thrombosis can also develop in patients with cirrhosis and in those with porto-sinusoidal vascular liver disease. The presence and nature of underlying liver disease impacts the management of portal vein thrombosis. Indications for anticoagulation in patients with cirrhosis are growing, while transjugular intrahepatic portosystemic shunt is now a second-line option. Due to the rarity of these diseases, studies yielding high-grade evidence are scarce. However, collaborative studies have provided new insight into the management of these patients. This article focuses on the causes, diagnosis, and management of patients with Budd-Chiari syndrome, portal vein thrombosis without underlying liver disease, or cirrhosis with non-malignant portal vein thrombosis. |
format | Online Article Text |
id | pubmed-10023986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-100239862023-03-19 Management of splanchnic vein thrombosis Elkrief, Laure Payancé, Audrey Plessier, Aurélie d’Alteroche, Louis Ronot, Maxime Paradis, Valérie Valla, Dominique Rautou, Pierre-Emmanuel JHEP Rep Review The expression splanchnic vein thrombosis encompasses Budd-Chiari syndrome and portal vein thrombosis. These disorders have common characteristics: they are both rare diseases which can cause portal hypertension and its complications. Budd-Chiari syndrome and portal vein thrombosis in the absence of underlying liver disease share many risk factors, among which myeloproliferative neoplasms represent the most common; a rapid comprehensive work-up for risk factors of thrombosis is needed in these patients. Long-term anticoagulation is indicated in most patients. Portal vein thrombosis can also develop in patients with cirrhosis and in those with porto-sinusoidal vascular liver disease. The presence and nature of underlying liver disease impacts the management of portal vein thrombosis. Indications for anticoagulation in patients with cirrhosis are growing, while transjugular intrahepatic portosystemic shunt is now a second-line option. Due to the rarity of these diseases, studies yielding high-grade evidence are scarce. However, collaborative studies have provided new insight into the management of these patients. This article focuses on the causes, diagnosis, and management of patients with Budd-Chiari syndrome, portal vein thrombosis without underlying liver disease, or cirrhosis with non-malignant portal vein thrombosis. Elsevier 2023-01-03 /pmc/articles/PMC10023986/ /pubmed/36941824 http://dx.doi.org/10.1016/j.jhepr.2022.100667 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Elkrief, Laure Payancé, Audrey Plessier, Aurélie d’Alteroche, Louis Ronot, Maxime Paradis, Valérie Valla, Dominique Rautou, Pierre-Emmanuel Management of splanchnic vein thrombosis |
title | Management of splanchnic vein thrombosis |
title_full | Management of splanchnic vein thrombosis |
title_fullStr | Management of splanchnic vein thrombosis |
title_full_unstemmed | Management of splanchnic vein thrombosis |
title_short | Management of splanchnic vein thrombosis |
title_sort | management of splanchnic vein thrombosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023986/ https://www.ncbi.nlm.nih.gov/pubmed/36941824 http://dx.doi.org/10.1016/j.jhepr.2022.100667 |
work_keys_str_mv | AT elkrieflaure managementofsplanchnicveinthrombosis AT payanceaudrey managementofsplanchnicveinthrombosis AT plessieraurelie managementofsplanchnicveinthrombosis AT dalterochelouis managementofsplanchnicveinthrombosis AT ronotmaxime managementofsplanchnicveinthrombosis AT paradisvalerie managementofsplanchnicveinthrombosis AT valladominique managementofsplanchnicveinthrombosis AT rautoupierreemmanuel managementofsplanchnicveinthrombosis |